Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104471 | 0.78 | FAAH (0.48) | FAAHPHGDHMGLLATMNOS2 | |
| SCHEMBL10431258 | 0.76 | FAAH (0.45) | FAAHPHGDHMGLLATMNOS2 | |
| SCHEMBL4092988 | 0.76 | FAAH (0.45) | FAAHPHGDHMGLLATMNOS2 | |
| Hydrochloric Acid SCHEMBL31256658 | 0.69 | — | — | |
| SCHEMBL26823966 | 0.68 | L3MBTL3 (0.34) | HRH3KCNH2 | |
| SCHEMBL22602112 | 0.67 | — | — | |
| SCHEMBL12568612 | 0.66 | DPP4 (0.40) | HRH3KCNH2DPP4 | |
| SCHEMBL13874912 | 0.66 | DPP4 (0.40) | HRH3KCNH2DPP4 | |
| SCHEMBL16187050 | 0.66 | ALDH1A1 (0.38) | KMT2A | |
| SCHEMBL9927929 | 0.66 | DPP4 (0.40) | HRH3KCNH2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197527-A1 | STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN | ZYMEWORKS BC INC. (CA) | 2025-06-19 | — | — | US | disclosed |
| EP-4519525-A1 | LATCHING MECHANISM FOR A MOVEABLE PANEL | Fort Noxs B.V. (NL) | 2025-03-12 | — | — | EP | disclosed |
| US-20250034251-A1 | ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-30 | — | — | US | disclosed |
| US-11939379-B2 | Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023213819-A1 | LATCHING MECHANISM FOR A MOVEABLE PANEL | FORT NOXS B.V. (NL) | 2023-11-09 | — | — | WO | disclosed |
| EP-3460095-B1 | SLIDING MEMBER | KK RIKEN (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034251-A1 | ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES | BID, BAD, BCL2L10 | OPRM1 4590/4885FAAH 2393/4885PHGDH 4431/4885 |
| US-11939379-B2 | Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies | BID, BAD, BCL2L10 | OPRM1 4590/4885FAAH 2393/4885PHGDH 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.